Literature DB >> 25015314

UTP is not a biased agonist at human P2Y(11) receptors.

Gael B Morrow, Robert A Nicholas, Charles Kennedy.   

Abstract

Biased agonism describes a multistate model of G protein-coupled receptor activation in which each ligand induces a unique structural conformation of the receptor, such that the receptor couples differentially to G proteins and other intracellular proteins. P2Y receptors are G protein-coupled receptors that are activated by endogenous nucleotides, such as adenosine 5′-triphosphate (ATP) and uridine 5′-triphosphate (UTP). A previous report suggested that UTP may be a biased agonist at the human P2Y11 receptor, as it increased cytosolic [Ca2+], but did not induce accumulation of inositol phosphates, whereas ATP did both. The mechanism of action of UTP was unclear, so the aim of this study was to characterise the interaction of UTP with the P2Y11 receptor in greater detail. Intracellular Ca2+ was monitored in 1321N1 cells stably expressing human P2Y11 receptors using the Ca2+-sensitive fluorescent indicator, fluo-4. ATP evoked a rapid, concentration-dependent rise in intracellular Ca2+, but surprisingly, even high concentrations of UTP were ineffective. In contrast, UTP was slightly, but significantly more potent than ATP in evoking a rise in intracellular Ca2+ in 1321N1 cells stably expressing the human P2Y2 receptor, with no difference in the maximum response. Thus, the lack of response to UTP at hP2Y11 receptors was not due to a problem with the UTP solution. Furthermore, coapplying a high concentration of UTP with ATP did not inhibit the response to ATP. Thus, contrary to a previous report, we find no evidence for an agonist action of UTP at the human P2Y11 receptor, nor does UTP act as an antagonist.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25015314      PMCID: PMC4272372          DOI: 10.1007/s11302-014-9418-3

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  16 in total

1.  Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.

Authors:  Lucien Gazi; Sarah A Nickolls; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

2.  Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase.

Authors:  D Communi; C Govaerts; M Parmentier; J M Boeynaems
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

3.  Differential coupling of the human P2Y(11) receptor to phospholipase C and adenylyl cyclase.

Authors:  A D Qi; C Kennedy; T K Harden; R A Nicholas
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor.

Authors:  C Kennedy; A D Qi; C L Herold; T K Harden; R A Nicholas
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

5.  Pharmacological characterization of the human P2Y11 receptor.

Authors:  D Communi; B Robaye; J M Boeynaems
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.

Authors:  R A Nicholas; W C Watt; E R Lazarowski; Q Li; K Harden
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

7.  The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Maria Teresa Miras-Portugal; Brian F King; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Trends Pharmacol Sci       Date:  2005-01       Impact factor: 14.819

8.  Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.

Authors:  Pamela J White; Tania E Webb; Michael R Boarder
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

Authors:  K A Berg; S Maayani; J Goldfarb; C Scaramellini; P Leff; W P Clarke
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

10.  Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate.

Authors:  E R Lazarowski; W C Watt; M J Stutts; R C Boucher; T K Harden
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more
  4 in total

Review 1.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

2.  Characterisation of P2Y2 receptors in human vascular endothelial cells using AR-C118925XX, a competitive and selective P2Y2 antagonist.

Authors:  Markie O Muoboghare; Robert M Drummond; Charles Kennedy
Journal:  Br J Pharmacol       Date:  2019-07-06       Impact factor: 8.739

3.  Purinergic control of lysenin's transport and voltage-gating properties.

Authors:  Sheenah Bryant; Nisha Shrestha; Paul Carnig; Samuel Kosydar; Philip Belzeski; Charles Hanna; Daniel Fologea
Journal:  Purinergic Signal       Date:  2016-06-18       Impact factor: 3.765

4.  UTP - Gated Signaling Pathways of 5-HT Release from BON Cells as a Model of Human Enterochromaffin Cells.

Authors:  Andromeda Liñán-Rico; Fernando Ochoa-Cortes; Alix Zuleta-Alarcon; Mazin Alhaj; Esmerina Tili; Josh Enneking; Alan Harzman; Iveta Grants; Sergio Bergese; Fievos L Christofi
Journal:  Front Pharmacol       Date:  2017-07-13       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.